Philipp Buchgraber

This inventor holds 23 USPTO granted patents and 10 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft, The Broad Institute, Inc.. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Philipp Buchgraber. Retrieved from https://idiyas.com/inventor/philipp-buchgraber

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 10)

% Patents Active = 82.6

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 26)

Average Co-Inventor Count = 15.5

ph-index = 4

Forward Citations = 71(Granted Patents)

Location History:

Wuppertal, DE (2015 - 2020)
Berlin, DE (2016 - 2021)
Leverkusen, DE (2022 - 2024)

Company Filing History:

21 out of 387

Bayer Pharma Aktiengesellschaft

patents

9 out of 12,269

Bayer Aktiengesellschaft

patents

8 out of 490

The Broad Institute, Inc.

patents

4. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Adrenoreceptor Inhibitors

Indole Derivatives

Piperidinyl Compounds

Macrocyclic Compounds

Amino-Substituted Imidazoles

Fluorine Substituted Indoles

Chlorine Substituted Indoles

Tetrahydroquinolines

Carboxamides

Azole Compounds

Pyrazolo-Pyridines

Bipiperidinyl Derivatives

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12540134 - Inhibitors of adrenoreceptor ADRAC2 (2026-02-03),

2. 12152041 - Macrocyclic fluorine substituted indole derivatives (2024-11-26),

3. 11891404 - Substituted macrocyclic indole derivatives (2024-02-06),

4. 11492358 - Macrocyclic indole derivatives (2022-11-08),

5. 11478451 - Macrocyclic chlorine substituted indole derivatives (2022-10-25),

6. 11447504 - Macrocyclic chlorine substituted indole derivatives (2022-09-20),

7. 11440923 - Substituted macrocyclic indole derivatives (2022-09-13),

8. 11401278 - Macrocyclic indole derivatives (2022-08-02),

9. 11286263 - Macrocyclic fluorine substituted indole derivatives (2022-03-29),

10. 10981932 - Macrocyclic indole derivatives (2021-04-20),

11. 10961221 - Substituted piperidinyl tetrahydroquinolines (2021-03-30),

12. 10662185 - Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use (2020-05-26),

13. 10323020 - Substituted piperidinyl tetrahydroquinolines (2019-06-18),

14. 10052312 - Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use (2018-08-21),

15. 9944621 - Substituted piperidinyl tetrahydroquinolines (2018-04-17),

Title: Innovator Spotlight: Philipp Buchgraber, Pioneering Inventor in Pharmaceutical Compounds

Introduction:

Philipp Buchgraber, a prolific inventor based in Berlin, Germany, has made significant contributions to the field of pharmaceuticals with his groundbreaking innovations. With a keen focus on developing novel compounds for treating hyperproliferative disorders, Philipp has achieved remarkable success in his career as an inventor.

Latest Patents:

Philipp Buchgraber's latest patents showcase his expertise in designing substituted macrocyclic indole derivatives and macrocyclic indole derivatives. These compounds, outlined in detailed formulas, have paved the way for new methods of preparation, intermediate compounds, pharmaceutical compositions, and treatment approaches for various diseases, particularly hyperproliferative disorders.

Career Highlights:

With an impressive portfolio of 21 patents to his name, Philipp Buchgraber has established himself as a leading figure in the pharmaceutical innovation landscape. His dedication to research and development has led to the creation of cutting-edge compounds that show promise in the treatment and prophylaxis of challenging medical conditions.

Collaborations:

During his professional journey, Philipp Buchgraber has collaborated closely with esteemed colleagues such as Frank Wunder and Gorden Redlich. Their combined expertise and shared vision for advancing pharmaceutical research have undoubtedly influenced the success of their collaborative projects.

Conclusion:

In conclusion, Philipp Buchgraber's pioneering work in inventing pharmaceutical compounds reflects his unwavering commitment to innovation and scientific advancement. His impactful patents not only demonstrate his technical proficiency but also underscore his dedication to improving healthcare outcomes for individuals worldwide. Through his collaborations and contributions to the field, Philipp continues to inspire future generations of inventors and researchers in the pharmaceutical industry.

Profile summary based on public USPTO records.